Patents by Inventor Ronald A. DePinho

Ronald A. DePinho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Myc homology region II-associated protein and uses thereof
    Publication number: 20020120104
    Abstract: The present invention provides a novel MHRII-associated protein designated MHRII-AP62 and antibodies immunoreactive with the MHRII-AP62 protein. Also provided are kits containing these antibodies and methods of using the antibodies for the detection of the MHRII-AP62 protein. The present invention also provides for a nucleic acid encoding the MHRII-AP62 protein and nucleic acid probes for use in the detection of the MHRII-AP62 protein. Further provided by the present invention are agents that mimic the activity of the MHRII-AP62 protein by binding to the MHRII, agents that inhibit the activity of the MHRII-AP62 protein by binding to the MHRII-AP62 protein, or by binding to the nucleic acid encoding the MHRII-AP62 protein, and methods of using these agents to treat cancer and cancer causing diseases.
    Type: Application
    Filed: August 3, 2001
    Publication date: August 29, 2002
    Inventor: Ronald A. DePinho
  • Myc homology region II—associated protein and uses thereof
    Patent number: 6297368
    Abstract: The present invention provides a novel MHRII-associated protein designated MHRII-AP62 and antibodies immunoreactive with the MHRII-AP62 protein. Also provided are kits containing these antibodies and methods of using the antibodies for the detection of the MHRII-AP62 protein. The present invention also provides for a nucleic acid encoding the MHRII-AP62 protein and nucleic acid probes for use in the detection of the MHRII-AP62 protein. Further provided by the present invention are agents that mimic the activity of the MHRII-AP62 protein by binding to the MHRII, agents that inhibit the activity of the MHRII-AP62 protein by binding to the MHRII-AP62 protein, or by binding to the nucleic acid encoding the MHRII-AP62 protein, and methods of using these agents to treat cancer and cancer causing diseases.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: October 2, 2001
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Ronald A. DePinho
  • Rep-max protein having anti-oncogenic activity and uses thereof
    Patent number: 6140476
    Abstract: The present invention provides a rep-max fusion gene which encodes a Rep-max protein capable of suppressing the oncogenic activity of a Myc family oncoprotein. The present invention further provides a vector containing nucleic acid encoding a Rep-max protein, a vector capable of expressing Rep-max protein and a recombinant viral vector capable of introducing nucleic acid encoding Rep-max protein into a target cell. Finally, the present invention provides a method for suppressing the oncogenic activity of the Myc family oncoproteins in a tumor cell and for inhibiting the growth of a tumor in a subject.
    Type: Grant
    Filed: September 22, 1998
    Date of Patent: October 31, 2000
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Ronald DePinho, Nicole Schreiber-Agus
  • Myc homology region II--associated protein
    Patent number: 6040425
    Abstract: The present invention provides a novel MHRII-associated protein designated MHRII-AP62 and antibodies immunoreactive with the MHRII-AP62 protein. Also provided are kits containing these antibodies and methods of using the antibodies for the detection of the MHRII-AP62 protein. The present invention also provides for a nucleic acid encoding the MHRII-AP62 protein and nucleic acid probes for use in the detection of the MHRII-AP62 protein. Further provided by the present invention are agents that mimic the activity of the MHRII-AP62 protein by binding to the MHRII, agents that inhibit the activity of the MHRII-AP62 protein by binding to the MHRII-AP62 protein, or by binding to the nucleic acid encoding the MHRII-AP62 protein, and methods of using these agents to treat cancer and cancer causing diseases.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: March 21, 2000
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Ronald A. DePinho
  • Transgenic mice having modified cell-cycle regulation
    Patent number: 5919997
    Abstract: The present invention relates to transgenic mice in which the biological function of at least one cell cycle regulatory proteins of the INK4 family is altered.
    Type: Grant
    Filed: April 4, 1996
    Date of Patent: July 6, 1999
    Assignees: Cold Spring Habor Labortary, Albert Einstein College of Medicine of Yeshiva University
    Inventors: David H. Beach, Manuel Serrano, Ronald A. DePinho
  • Rep-max protein having anti-oncogenic activity and uses thereof
    Patent number: 5811298
    Abstract: The present invention provides a rep-max fusion gene which encodes a Rep-max protein capable of suppressing the oncogenic activity of a Myc family oncoprotein. The present invention further provides a vector containing nucleic acid encoding a Rep-max protein, a vector capable of expressing Rep-max protein and a recombinant viral vector capable of introducing nucleic acid encoding Rep-max protein into a target cell. Finally, the present invention provides a method for suppressing the oncogenic activity of Myc family oncoproteins in a tumor cell and for inhibiting the growth of a tumor in a subject.
    Type: Grant
    Filed: February 29, 1996
    Date of Patent: September 22, 1998
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: Ronald DePinho, Nicole Schreiber-Agus